Company Reports

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with the acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

LivaNova delivered second-quarter results that featured revenue growth of 10% in constant currency. Operating margin fell 270 basis points thanks to unusual legal expenses. Management raised 2026 guidance for sales by 1 percentage point and earnings per share by $0.10 at the midpoint.

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with the acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

LivaNova posted first-quarter revenue (constant currency) and adjusted earnings growth of 11% and 29%, respectively. Management raised 2026 revenue growth guidance by 100 basis points and adjusted EPS by $0.05 at the midpoint.

Livanova reported revenue growth of 10% (in constant currency) for both the fourth quarter and full-year 2025. This was fueled by 13% and 7% increases in cardiopulmonary and neuromodulation revenue in 2025, respectively.

During Livanova's investor day, management provided a detailed look at the firm's plan to commercialize its hypoglossal nerve stimulation device to treat obstructive sleep apnea.

LivaNova's second quarter featured 9% top-line growth in constant currency and an operating margin that was 150 basis points higher than the prior-year period.

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with the acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

Livanova started 2025 in strong shape as quarterly revenue grew above our expectations at 8% and boosted adjusted operating income by 58%.

As a smaller medical-device firm, Livanova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

Livanova reported soft fourth-quarter results with 5% revenue growth in constant currency, while adjusted earnings per share fell by 7% primarily due to less favorable tax treatment.

LivaNova's strong third quarter rested on impressive top-line growth of 11% in constant currency and more-efficient cost management, with selling, general, and administrative margin improving 600 basis points year over year.

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

Narrow-moat LivaNova extended its strength from early in the year through the second quarter with results that slightly exceeded our expectations. With two quarters of outperformance under its belt, we expect to moderately raise our fair value estimate. We think tighter execution and the rollout of its new Essenz heart-lung machine have given LivaNova an opportunity to ramp up growth in its cardiopulmonary segment. The US market has been particularly responsive, with year-to-date growth of 29%. This strong performance and solid results from the neuromodulation business buy the new management team time to sort out the rest.

Narrow-moat Livanova posted first-quarter results that exceeded our expectations on the topline but were consistent with our profitability projections. We continue to hold more tempered views for slower growth in the second half of 2024, which is consistent with management's comments and, as a result, our fair value estimate is unchanged. Though quarterly revenue grew strongly at 12% year over year, below-the-line charges pushed earnings down. Considering that new CEO Vladimir Makatsaria is eager to demonstrate positive results now that he's leading the charge, we wouldn't be surprised if above-market growth could extend through the second quarter, aided by the regulatory and supply issues with oxygenators from competitors. If competitive oxygenators are able to return to the market in the second half of 2024, as expected, we anticipate Livanova's cardiopulmonary business could see noticeable moderation.

As a smaller medical-device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable and, with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal research and development, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

LivaNova delivered fourth-quarter and full-year results that ran slightly ahead of our expectations on the top line and slightly below on the bottom line largely due to impairment charges. We’re leaving our fair value estimate unchanged. Full-year revenue increased 13% in constant currency, fueled by exceptional 18% growth in cardiopulmonary, as adoption of new heart-lung machine Essenz has ramped up. We anticipate this growth to moderate in 2024 as capital spending on those platforms softens.

Narrow-moat LivaNova reported robust third-quarter results that ran slightly ahead of our expectations on the top line, but our slight adjustments to our near-term estimates weren’t enough to materially shift our fair value estimate. The shares remain fairly valued, in our view.

As a smaller medical device firm, LivaNova follows the same innovation strategy that has been successful for many larger competitors, including Medtronic and Boston Scientific. With this approach, manufacturers can create differentiated products that are not entirely interchangeable, and with each iteration of the technology, can eke out a pricing premium. The success of this strategy hinges on two factors. First, firms must be able to generate meaningful innovation. This usually happens through internal R&D, potentially augmented with acquisition of emerging technologies. Very rarely have we seen medical technology firms succeed solely on acquisition of technology. Second, successful commercialization also depends on a salesforce that has built strong relationships with the practitioners making the brand choice.

LivaNova’s second-quarter performance demonstrated a continuation of the strength seen in the first quarter, and after adjusting our full-year estimates upward, we plan to raise our fair value estimate modestly. The 16% organic revenue growth seen in the second quarter was broad-based both in terms of product lines and geography. Though we anticipate some factors contributing to the outsized performance in the first half of 2023 to moderate—such as easy comparable quarters, the temporary absence of an oxygenator competitor on the market—we think underlying demand should remain solid thanks to the resumption of the procedure referral pipeline, the rollout of Essenz heart-lung machine in Europe and the U.S., and the replacement cycle for its vagus nerve stimulation to address treatment-resistant epilepsy. We saw little to change our view of LivaNova’s narrow economic moat in second quarter.